Several polymorphic genetic systems have been used to study human genetic variation. Herein we report for a sample from the Ivory Coast on the frequencies of three polymorphic metabolic genes that have been found to play an important role in the metabolism of a relevant number of human carcinogens: the Cytochrome P450 1A1 (*CYP1A1*), the Glutathione S-transferases (*GST*) *T1* and the *GSTM1* genes. Several published studies pointed to ethnic differences in the frequencies of gene polymorphisms, shown to be associated with several types of cancer. The *CYP1A1* gene is a component of the phase I cytochrome P450 superfamily, which plays a primary role in the metabolism of polycyclic aromatic hydrocarbons. Its gene product catalyses the first step in the conversion of several environmental carcinogens into their ultimate DNA-binding carcinogenic form (for a review see [@IndulskiandLutz2000]). The human *CYP1A1* gene is highly polymorphic. In certain populations, such as the Japanese and Chinese, the amino acid substitution CYP1A1 Ile(462)Val has been reported to be associated with a higher risk of certain types of cancer, as lung cancer ([@Chenetal2001]), although in other populations, evidence of this association lacks support ([@McGrathetal2007]). These contradictory results could be explained by the distinct genetic backgrounds of the investigated populations, as well as other non-genetic factors.

Glutathione S-transferases, found in virtually all eukaryotes, represent one of the major groups of phase II detoxifying enzymes, having evolved to provide organic protection against toxic substances present in food and the environment ([@Nebertetal1996]). The mechanism involves the binding of glutathione to insoluble electrophilic substrates, thereby converting them into a soluble form ([@Perera1997]). *GSTT1* and *GSTM1* genes have long been known to be polymorphic in humans by the deletion of a segment of DNA, with the subsequent lack of protein synthesis in homozygous individuals. As a result of deletions at either of the two loci, and the consequent reduced detoxification of xenobiotics, an individual may become susceptible to diseases produced by toxic substances present in the environment ([@Royetal2001]). Deletion polymorphism in *GST* genes (non-functional alleles) has been found to be associated with the development of certain types of cancer, such as oral cancer ([@Chaetal2007]), chronic myeloid leukaemia ([@Bajpaietal2007]), bladder cancer ([@Ouerhanietal2006]), and colon cancer ([@Gertigetal1998]). Although variability in the distribution of *GSTM1* and *GSTT1* null genotypes has been reported in diverse ethnic groups ([@Nelsonetal1995]; [@Garteetal2001]), sparse data are available for West Africa ([@Wildetal2000]). The aim herein was to investigate the genetic variability at *CYP1A1* and *GSTs* loci in an African population from the Ivory Coast, for which no data has been published to date on metabolic gene polymorphisms.

Sampling was undertaken in Ouangolodougou, a small rural town of 20,000 inhabitants located in the north Ivory Coast, this representing the last frontier zone between the Ivory Coast, Mali and Burkina Faso. One hundred and thirty-three individuals (62 males and 71 females, mean age 31.9 ± 14,5) were analyzed. All were healthy volunteers and had received prior information regarding the study.

Peripheral blood samples (5-10 mL venipuncture) were collected in heparinized vacutainers and stored at -20 °C. The Chelex^®^ solution protocol was used to extract DNA, as described by [@Walshetal1991]. *GSTM*, *GSTT1 and CYP1A1* genotypes were defined by polymerase chain reaction (PCR), using primers and reaction profiles as described by [@Zhongetal1993], [@Pembleetal1994] and [@Chenetal2001], respectively. PCR reactions were carried out in a total volume of 25 μL containing 10 ng of DNA (template), with a final concentration of 1X Reaction Buffer, 1.5 mM of MgCl~2~, 5% of DMSO, 250 μM of dNTPs, 0.5 μM of each primer, and 1 U/sample of Taq DNA polymerase (Fischer, U.S.). PCR products were separated by electrophoresis on a 3% agarose gel and visualized by ethidium bromide staining. The expected size of amplified *CYP1A1* products was 162 base pairs (bp), whereas in the case of *GSTM1*, *GSTT1* and β*-globine* (used as internal control), the expected sizes were 230, 480 and 110 bp, respectively. Homozygous null genotypes of *GSTM1* and *GSTT1* were determined by identifying the negative band for each size (with the simultaneous presence of the positive control), whereas positive bands meant the sample was homo- or heterozygous for the indicated alleles. A genotype with homozygous deletion of the *GST* genes is denominated "*GST*-null", whereas a genotype having at least one copy of the gene is "*GST*-positive". In order to validate the obtained results, about 20% of the total sample (n = 30) was genotyped independently by a second researcher.

Allele and genotype frequencies of the *CYP1A1* gene were calculated using GENEPOP Version 4.0 ([@RaymondandRousset1995]). Hardy-Weinberg equilibrium (HWE) and comparisons among age-groups were evaluated by the Chi-square (χ^2^) test with a 95% confidence interval. Observed allele frequencies were also compared with those reported for other populations worldwide, through the analysis of contingency tables also by χ^2^-testing.

The frequencies of *CYP1A1* and *GSTs* allelic polymorphisms in a sample from the north Ivory Coast population, were analyzed. No significant differences were found between men and women in the allele frequency of each gene (p \> 0.05), thus possibly implying the absence of differences by sex in these detoxifying enzymes.

The observed frequencies of the *CYP1A1* Ile/Ile (wild type), Ile/Val (heterozygous variant) and Val/Val (homozygous variant) genotypes were 0.271, 0.692, and 0.037, respectively ([Table 1](#t1){ref-type="table"}). Differences in *CYP1A1* allele frequency distribution were reported among various ethnic groups ([@Garte1998]; [@Garteetal2001]). In the studied Ivory Coast population, \*Val allele frequency was significantly (p \< 0.001) high (0.383), as compared to the few data published for Africans ([Table 2](#t2){ref-type="table"}). This difference in *CYP1A1* polymorphism distribution among Africans could probably be attributed to the different evolutionary histories of the studied ethnic groups, although, as this polymorphism is not neutral, the distinctive selective pressure exerted by chemicals on different populations cannot be excluded. The high heterozygosity frequency value found for *CYP1A1* gene (0.692) is congruent with many global surveys of genetic markers, these indicating that diversity in African populations is consistently greater than in other populations ([@GarriganandHammer2006]). On the other hand, the excess of heterozygotes gave rise to a deviation from HWE (p \< 0.05). Moreover, a selective pressure exerted by xenobiotics on this population cannot be excluded. Although this possibility is consistent with several studies showing the association of this polymorphic gene with risk factors for diseases ([@Chenetal2001]), convincing evidence to suggest a role of these polymorphisms in modulating susceptibility to cancer diseases, is lacking ([@McGrathetal2007]).

Differences in *GSTT1* and *GSTM1* frequencies in populations worldwide have already been described ([@Nelsonetal1995]; [@Garteetal2001]). These differences show that *GST* genotype frequencies are distributed populationwise according to the various ethnic and geographical patterns ([@Garteetal2001]; [@Hatagimaetal2004]). In our sample, the frequencies of *GSTM1* and *GSTT1* null genotypes were 0.361 and 0.331 respectively, whereas the frequency of individuals lacking both genes was 0.143 ([Table 1](#t1){ref-type="table"}). GST genotypes were coded as positive (wild-type homozygotes and deletion heterozygotes) or null (homozygous deletion), thereby making direct calculation of HWE impossible. Among Africans, no differences were encountered between the population studied and others analyzed for the *GSTT1* locus, whereas for *GSTM1* significant differences (p \< 0.05) were found with respect to Gambia (0.200, [@Wildetal2000]) and Egypt (0.555, [@Hamdyetal2003]). In Africa, the genetic structure of many otherwise genetically "neutral" systems, such as mitochondrial DNA variation, has already been demonstrated ([@Salasetal2002]). Therefore, it is not surprising to discover differences between west and north African populations. The significant difference in frequency of *GTSM1*-null alleles between the Ivory Coast, Gambian and Egyptian populations could probably be attributed to diversity in populational history. Moreover, data on the prevalence of various diseases, especially those related to local exposure to toxic substances, are unavailable. Therefore, among Africans it is difficult to ascertain the cause of ethnic variation in the frequency of "null" genotypes, and the implications therefrom on the epidemiological profiles of metabolic diseases.

In conclusion, we reported on novel frequency data as regards *CYP1A1*, *GSTM1* and *GSTT1* gene polymorphisms in a north Ivory Coast population, thereby extending previous observations obtained from other African populations. Although these gene polymorphisms are not neutral, and thus cannot be used in anthropological studies as genetic markers are subject to stochastic processes, knowledge of their frequency distribution in the Ivory Coast could be helpful in understanding their roles as genetic susceptibility markers in African populations.
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###### 

Genotype and allele Frequencies at *CYP1A1* and *GSTs* loci in the Ouangolodougou population (n = 133)

  Genotype                        Observed subjects (frequency)   Expected subjects (frequency)   χ^2^ (1 d.f.)   Allele (frequency)
  ------------------------------- ------------------------------- ------------------------------- --------------- --------------------
  *CYP1A1*                                                                                                        
  Ile/Ile                         36 (0.271)                      51 (0.383)                      4.41            Ile (0.617)
  Ile/Val                         92 (0.692)                      63 (0.474)                      13.35           Val (0.383)
  Val/Val                         5 (0.037)                       19 (0.143)                      10.32           
  Total                                                                                           28.08           
  *GSTM1*                                                                                                         
  Present                         85 (0.639)                                                                      
  Null                            48 (0.361)                                                                      
  *GSTT1*                                                                                                         
  Present                         89 (0.669)                                                                      
  Null                            44 (0.331)                                                                      
  *GSTM1* null and *GSTT1* null   19 (0.143)                                                                      

n = number of tested individuals.

###### 

Frequency of *CYP1A1* and *GSTs* null genotypes in certain African populations.

  Population           n     *GSTM1* null frequency   n       *GSTT1* null frequency   Reference
  -------------------- ----- ------------------------ ------- ------------------------ -------------------------
  Africans             114   0.330                    114     0.250                    [@Dandaraetal2002]
  Africans             479   0.267                                                     [@Garteetal2001]
  Egypt                200   0.555                    200     0.295                    [@Hamdyetal2003]
  Gambia               337   0.202                    326     0.371                    [@Wildetal2000]
  Ivory Coast          133   0.361                    133     0.331                    Present study
  Tunisia              79    0.456                    79      0.443                    [@Ouerhanietal2006]
                                                                                       
  Population           n     *Ile* allele frequency                                    Reference
                                                                                       
  Africans             114   114                      0.987                            [@Dandaraetal2002]
  Africans             445   445                      0.993                            [@Garteetal2001]
  African-Americans    290   290                      0.969                            [@Taiolietal1998]
  African-Americans    539   539                      0.970                            [@Garte1998]
  African-Brazilians   231   231                      0.855                            [@Gasparetal2002]
  African-Brazilians   21    21                       0.905                            [@Hamadaetal1995]
  Benin                94    94                       1.000                            [@Jiangetal2005]
  Ivory Coast          133   133                      0.617                            Present Study
  Mali                 116   116                      1.000                            [@Garte1998]
  Zimbabwe             225   225                      1.000                            [@Masimirembwaetal1998]

n = number of tested individuals.
